SION | Ticker Profile - Titan Protect

SION

Sionna Therapeutics, Inc.

Healthcare · Biotechnology · NGM

$35.37

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.0B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-15.50

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-26.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$54.00

+53% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 10 analysts covering this stock

About Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

https://www.sionnatx.com

Country: United States Employees: 59 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.906

Good returns relative to risk taken

Kelly Fraction

0.0665

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.740

Acceptable balance between returns and drawdown risk

Annual Return

51.3%

Historical annualised return based on price data

Max Drawdown

-69.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$48.45

27% below the year high

52W Low

$12.71

178% above the year low

Avg Volume

378,185

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

17.1%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.86

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.91

Heavy leverage — higher financial risk if revenues decline

Current Ratio

22.60

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

22.11

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-45,699,248

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-85,565,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$63.00

Target Median

$54.00

Target Low

$23.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
30 Apr2026	Dave McCormick	Republican	sell	250K–500K
30 Apr2026	Dave McCormick	Republican	sell	50K–100K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go